<DOC>
	<DOCNO>NCT00035919</DOCNO>
	<brief_summary>This Phase I safety study gene transfer drug colorectal cancer spread liver . The main purpose study determine safe give new intervention person cancer , also look indication drug effective . Although findings animal cancer encouraging , first time human receive experimental gene transfer drug . A gene call cyclin G1 show play important part cancer growth . In animal experiment , genetically modify virus ( vector ) carry modify cyclin G1 gene cause cancerous tumor grow much slow even die . In safety study , drug inject liver artery get near cancer spread liver . The way gene get cancer cell use targeted vector concentrate area cancer improve delivery kill gene cancer cell . The vector use virus change infectious gene remove instead carry modify cyclin G1 gene .</brief_summary>
	<brief_title>Safety Efficacy Targeted Gene Transfer Colorectal Cancer Metastatic Liver</brief_title>
	<detailed_description>Objectives : 1 . To evaluate safety/toxicity hepatic arterial administration matrix-targeted retroviral vector bear dnG1 construct ( Mx-dnG1 ) 2 . To evaluate pharmacodynamics hepatic arterial infusion Mx-dnG1 retroviral vector administer hepatic arterial infusion . 3 . To obtain preliminary data molecular marker tumor response 4 . To identify anti-tumor response hepatic artery administer Mx-dnG1 retroviral vector Population : Male female patient , &gt; 18 year old , metastatic colorectal carcinoma Sample Size : Nine fifteen patient ( 3 6 patient treat three dose level ) . Dosage Treatment : Hepatic arterial infusion Mx-dnG1 retroviral vector day day 1-5 . Three patient receive Mx-dnG1 retroviral vector Dose Level I . If 1 3 patient Dose Level I develop grade 3 4 adverse event ( CTC Version 2.0 ) appear relate possibly relate Mx-dnG1 retroviral vector , 3 additional patient enrol dose level . If least 2 first 3 , 3 6 , patient Dose Level I develop grade 3 4 adverse event appear relate possibly relate Mx-dnG1 retroviral vector , accrual study hold data discuss Food Drug Administration ( FDA ) decision make whether continue terminate study enrollment . If none first 3 1 first 6 patient receive vector Dose Level I develop grade 3 4 adverse event appear relate possibly relate dnG1 retroviral vector , dose vector escalate follow : Dose LeveL -- -No . Patients -- -Vector Dose -- -Maximum Volume - I -- -- -- -- -- -- -- -- 3 -- -- -- -- -- -- 3 X 10e9 cfu -- -- -- -500 ml - II -- -- -- -- -- -- -- -3 -- -- -- -- -- -- 6 X 10e9 cfu -- -- -- -500 ml - III -- -- -- -- -- -- -- 3 -- -- -- -- -- -- 1 X 10e10 cfu -- -- -- 500 ml The intervention plan identical one describe Dose Level I . The Maximum Tolerated Dose ( MTD ) define one dose level level dose limit toxicity observe . Primary Endpoint : Clinical toxicity ( DLT MTD ) define patient performance status , toxicity assessment score , hematologic , liver coagulation profile . Secondary Endpoint : Obtain preliminary data molecular marker tumor response . To assess decrease tumor size detect abdominal CT Scan 3 6 week treatment . Evaluate pharmacodynamics hepatic arterial infusion Mx-dnG1 retroviral vector administer hepatic arterial infusion .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Patients consider candidate propose protocol patient fail standard chemotherapy regimen ( 5FU , LV CPT11 ) , judgment principal investigator , meet follow criterion : 1 . Histologically cytologically confirm colorectal carcinoma metastatic liver , unresectable base judgment patient 's surgeon ) radiologically measurable . 2 . Adequate hepatic function : Total bilirubin &lt; 2.0 mg/dL ( upper limit include ) ; AST/ALT &lt; 2x institutional norm ; alkaline phosphatase &lt; 3x upper limit institutional norm , albumin &gt; 3.0 mg/dL . There must substantial ascites . PT PTT must within normal limit . 3 . Performance status must 01 ( SWOG 01 ) life expectancy least 3 month . 4 . Absolute granulocyte count &gt; 1000/uL , platelet count &gt; 100,000/uL . 5 . Calculated creatinine clearance &gt; 60ml/hour . 6 . There must plan patient receive cancer therapy date enrollment completion 12 week followup visit . 7 . Installation functional hepatic arterial infusion ( HAI ) satisfactory position catheter primary branch hepatic artery , place within prior 6 month three week . If patient presently hepatic artery infusion pump place , pump place might qualify participate intervention followup phase clinical trial . 8 . Age &gt; 18 year , order protect child minor potential risk new drug yet test adult . 9 . The ability understand willingness sign write informed consent document . Exclusion Criteria 1 . Prior malignancy , except nonmelanoma skin cancer , stage I breast cancer , CIS cervix patient disease free 5 year . 2 . Woman pregnant nursing 3 . Fertile patient unless agree use barrier contraception ( condoms spermicide jelly ) vector infusion period six week infusion . 4 . Patients medical , psychiatric , social condition would compromise successful adherence protocol . 5 . Patients indwell biliary stent recent history cholangitis , hepatitis , presence disseminate intravascular coagulopathy , HIV infection . Patients must history recent myocardial infarction ( within one year ) evidence congestive heart failure . 6 . Patients history bleeding varix prior 3 month . 7 . Patients receive antitumor treatment ( chemotherapy , radiation , immunotherapy ) within 4 week study entry recover previous therapy within 6 week mitomycin C nitrosureas .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Colon cancer</keyword>
	<keyword>Targeted Injectable Vector</keyword>
	<keyword>Gene Transfer</keyword>
	<keyword>Gene Therapy</keyword>
	<keyword>Retroviral vector</keyword>
</DOC>